Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

273
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
273
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

199
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
199
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

234
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
234
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

223
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
223
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

213
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
213

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Stiffness-dependent alveolar type II cell senescence in idiopathic pulmonary fibrosis.

Cell communication and signaling : CCS·2026
Same author

Prevalence of the phenotype of lung hyperinflation and minimal emphysema in COPD.

American journal of respiratory and critical care medicine·2026
Same author

Post-Pulmonary Embolism Syndrome: New Phenotypes Come into Focus.

Journal of clinical medicine·2026
Same author

Hair follicle gene expression profiling in the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS).

BMC medical genomics·2025
Same author

Emphysema detection by qualitative and quantitative analysis and relationship to spirometric obstruction in an urban comprehensive lung cancer screening programme: the Temple Healthy Chest Initiative (THCI) - a retrospective cohort study.

BMJ open·2025
Same journal

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same journal

Changes in Arterial-Alveolar Oxygen Gradient and Mixed Venous Oxygen Saturations in Mechanical Thrombectomy for Pulmonary Embolism: A Prospective Cohort Study.

Pulmonary circulation·2026
Same journal

Echocardiography-Derived Exercise Pulmonary Hypertension and Longitudinal Changes in Pulmonary Artery Pressures in Systemic Sclerosis: A Non-Invasive Assessment for Risk Stratification.

Pulmonary circulation·2026
Same journal

Sotatercept as a Therapeutic Option for Systemic Sclerosis-Associated Pulmonary Arterial Hypertension With Features of PVOD/PCH.

Pulmonary circulation·2026
Same journal

Patient Perspectives on Palliative Care in Pulmonary Arterial Hypertension in the United States.

Pulmonary circulation·2026
Same journal

Right Ventricular Mechanical Dyssynchrony Reflects Hemodynamic Load in Pre-Capillary Pulmonary Hypertension.

Pulmonary circulation·2026
See all related articles

Related Experiment Video

Updated: Jul 27, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

Pulmonary vasodilator therapy in sarcoidosis-associated pulmonary hypertension may decrease lung function decline and

Shameek Gayen1, Sohaib Ansari1, Bilal H Lashari1

  • 1Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University of Hospital Philadelphia Pennsylvania USA.

Pulmonary Circulation
|June 7, 2023
PubMed
Summary
This summary is machine-generated.

Pulmonary vasodilator therapy may slow functional vital capacity decline and improve survival in patients with sarcoidosis-associated pulmonary hypertension (SAPH). This retrospective study suggests potential benefits, warranting further investigation.

Keywords:
functional vital capacitylung transplantpulmonary hypertensionpulmonary vasodilator therapysarcoidosis

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.0K

Related Experiment Videos

Last Updated: Jul 27, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.0K

Area of Science:

  • Pulmonology
  • Cardiology
  • Rheumatology

Background:

  • Sarcoidosis-associated pulmonary hypertension (SAPH) treatment efficacy remains unclear.
  • Pulmonary vasodilator therapy has shown promise in other forms of pulmonary hypertension.

Purpose of the Study:

  • To evaluate the impact of pulmonary vasodilator therapy on functional vital capacity (FVC) decline in SAPH patients.
  • To compare survival rates and other clinical outcomes between treated and untreated SAPH patients.

Main Methods:

  • Retrospective analysis of 58 SAPH patients undergoing lung transplantation evaluation.
  • Comparison of FVC change, 6-minute walk distance (6MWD), oxygen requirements, transplant rates, and mortality between patients receiving pulmonary vasodilators and those who did not.

Main Results:

  • Patients treated with pulmonary vasodilators experienced significantly less FVC decline (+54 mL vs. -357 mL).
  • Treated SAPH patients demonstrated significantly higher survival rates.
  • Pulmonary vasodilator therapy was associated with improved FVC change and decreased mortality.

Conclusions:

  • Pulmonary vasodilator therapy may offer significant benefits in reducing FVC decline and improving survival in SAPH patients.
  • These findings support the potential role of pulmonary vasodilators in managing SAPH.
  • Further prospective studies are needed to confirm these benefits.